Brachyury peptide vaccine - NantCell

Drug Profile

Brachyury peptide vaccine - NantCell

Alternative Names: GI-6301; Yeast brachyury vaccine - NantCell

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlobeImmune
  • Developer GlobeImmune; NantKwest; National Cancer Institute (USA)
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Germ cell and embryonal neoplasms
  • Phase I/II Breast cancer; Colorectal cancer; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Jul 2018 NantKwest plans the QUILT-2.024 phase II trial for Non Small Cell Lung Cancer (Late-stage disease) in USA , (NCT03574649)
  • 20 Jun 2018 NantKwest plans the QUILT-3.088 phase II trial for Pancreatic Cancer (Metastatic disease) in USA , (NCT03563144)
  • 20 Jun 2018 NantKwest plans a phase II QUILT-3.057 trial for Triple negative breast cancer (First-line therapy, Combination therapy, Neoadjuvant therapy) in USA (NCT03554109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top